Jazz Pharmaceuticals, Inc.

JAZZ · Pharmaceutical Preparations · $15.6B
Cooling off
JAZZ
$240.74
▼ −1.27%
09/18 O 244.55 H 244.55 L 238.97 C 240.74 ▼ −1.27%
Vol 2.2M RS 84
RS rating84
Now vs pivot (%)−1.06%
Tightening (ATR ratio)1.03×
Volume dry-up1.06×
Up/down volume, net0.02
From 52-week high10%
squatfailed pokeplayed out
Previous breakout trailed out ▲ +23.42% in Apr
Cooling off
Moving averages
9-dayabout two weeks21-dayabout a month50-dayabout a quarter200-dayabout a year

The four are not in order. That is a description of where the averages sit, not a view about what happens next.

The read

The base has run 5.4 weeks and fell 9% from its ceiling at its deepest. The pivot is $243.32, and the stock closed 1.1% below it. Its relative strength rating is 84.

Also on
Peers
Catalyst roadmap
  1. EarningstentativeLLY · competitorin 41d
    LLY reports
    Oct 29, 2026
  2. Earningstentativein 47d
    Quarterly earnings
    Nov 4, 2026
Flagged by the market sweep

Nothing flagged for this company on the last market sweep.

In the news
Insiders

No Form 4 filings read for this company in the last six months. That can mean nobody filed, or that this name has not been on a screen long enough for us to have fetched them.

X-ray

A screening and market-analytics tool. Not investment advice. We are not a registered investment adviser. Historical figures are backtests and are hypothetical.

What that means, in full
Jazz Pharmaceuticals, Inc. (JAZZ) — The Tape